Separate current trading from historical accounts
The latest selected financial period is 2024-06-30. A recent market quote or a new scoring timestamp does not update those accounts.
—
—
—
FSD Pharma
—
—
Live Price
CIN COMPANY RESEARCH
Historical listing reviewCIN’s take on FSD Pharma
Review dated
FSD Pharma changed its name to Quantum BioPharma and its ticker to QNTM in August 2024. CIN treats the former cannabis operations and their asset sale as historical and would assess the successor on its disclosed biotechnology assets and funding.
Original sources
CIN RESEARCH · DATED EVIDENCE
Historical financial evidenceFSD Pharma: newer financial reporting is the missing piece.
The available financial series reaches June 30, 2024; current financial conclusions are withheld.
Latest financial observation 2024-06-30Price history through 2024-10-16Research checked 2026-11-08 13:31 UTC
The check time records a research refresh. Each financial figure and price keeps its own reporting date.
Reported financial evidence
| Measure | Reported value & unit | Period & interval | Evidence basis |
|---|---|---|---|
| RevenueHistorical observation | USD 0Unit: USD | Quarterly series | Dated financial series |
| Cost of revenueHistorical observation | USD 119,604Unit: USD | Quarterly series | Dated financial series |
| Gross profitHistorical observation | USD -119,604Unit: USD | Quarterly series | Dated financial series |
| Operating incomeHistorical observation | USD -3.47mUnit: USD | Quarterly series | Dated financial series |
| EBITDAHistorical observation | USD -2.12mUnit: USD | Quarterly series | Dated financial series |
| Net incomeHistorical observation | USD -3.11mUnit: USD | Quarterly series | Dated financial series |
| Cash balanceHistorical observation | USD 3.31mUnit: USD | Balance at period end | Dated financial series |
| Total assetsHistorical observation | USD 15.25mUnit: USD | Balance at period end | Dated financial series |
| Total liabilitiesHistorical observation | USD 5.04mUnit: USD | Balance at period end | Dated financial series |
| Shareholders’ equityHistorical observation | USD 10.96mUnit: USD | Balance at period end | Dated financial series |
| Operating cash flowHistorical observation | USD -606,482Unit: USD | Quarterly series | Dated financial series |
| Free cash flowHistorical observation | USD -606,482Unit: USD | Quarterly series | Dated financial series |
A balance at period end is not income over a period. “Quarterly series” follows the available classification; the source disclosure establishes the actual reporting interval.
What to investigate next
- Resolve the conflicting financial observations against the primary report.
- Locate a newer primary financial report and reconcile its units before making a current company assessment.
Evidence boundaries
- Conflicting observations for the same concept, period and reporting basis are withheld.
- The newest available revenue observation is historical on its supplied reporting basis. A current revenue assessment is withheld.
- No dated primary company disclosures were supplied; absence in this feed is not a clean regulatory check.
- Interim frequency is provider-classified. Generic form labels are not treated as proof of an SEC filing or a three-month reporting duration.
- The earlier rating is not presented as a current conclusion. This report is rebuilt from dated evidence.
Independent evidence summary. No broker consensus, price target or investment rating is manufactured. Research standards →
Price History · currency not supplied
5 Years
Fundamentals
SEC & Market Data
Loading fundamentals…
Analyst Consensus
Loading analyst data…
Valuation Multiples
Loading…
Price Statistics
Loading…
Financing Activity
Loading financing data…
Insider Transactions
Loading insider data…
Regulatory Filings
Loading regulator disclosures…
Peer Comparison
Loading peer data…
CONTINUE YOUR RESEARCH